G. S. Ginsburg and H. F. Willard, Genomic and personalized medicine: foundations and applications, Translational Research, vol.154, issue.6, pp.277-287, 2009.

R. Mirnezami, J. Nicholson, and A. Darzi, Preparing for precision medicine, New England Journal of Medicine, vol.366, pp.489-491, 2012.

M. Vidal, M. E. Cusick, and A. Barabási, Interactome networks and human disease, Cell, vol.144, issue.6, pp.986-998, 2011.

K. Strimbu and J. A. Tavel, What are Biomarkers?, Current Opinion in HIV and AIDS, vol.5, issue.6, pp.463-466, 2011.

P. Csermely, T. Korcsmàros, H. J. Kiss, G. London, and R. Nussinov, Structure and dynamics of molecular networks: A novel paradigm of drug discovery: A comprehensive review, Pharmacology and Therapeutics, vol.138, issue.3, pp.333-408, 2013.

Q. Zhong, N. Simonis, Q. Li, B. Charloteaux, F. Heuze et al., Edgetic perturbation models of human inherited disorders, Molecular Systems Biology, vol.5, issue.321, p.321, 2009.

P. Creixell, E. M. Schoof, C. D. Simpson, J. Longden, C. J. Miller et al., Kinome-wide decoding of network-attacking mutations rewiring cancer signaling, Cell, vol.163, issue.1, pp.202-217, 2015.

S. Kauffman, Homeostasis and differentiation in random genetic control networks, Nature, vol.224, pp.177-178, 1969.

R. Thomas, Boolean formalization of genetic control circuits, Journal of Theoretical Biology, vol.42, issue.3, pp.563-585, 1973.

C. S. Peirce, On the natural classification of arguments, Proceedings of the American Academy of Arts and Sciences, vol.7, pp.261-287, 1867.

W. Quine, On cores and prime implicants of truth functions, The American Mathematical Monthly, vol.66, issue.9, pp.755-760, 1959.

P. Marquis, Extending abduction from propositional logic to first order logic, Lecture Notes in Artificial Intelligence, vol.535, pp.141-155, 1991.

R. Layek, A. Datta, M. Bittner, and E. R. Dougherty, Cancer therapy design based on pathway logic, Bioinformatics, vol.27, issue.4, pp.548-555, 2011.

P. K. Lin and S. P. Khatri, Application of Max-SAT-based ATPG to optimal cancer therapy design, BMC Genomics, vol.13, issue.6, p.5, 2012.

D. Murrugarra, A. Veliz-cuba, B. Aguilar, and R. Laubenbacher, Identification of control targets in boolean molecular network models via computational algebra, BMC Systems Biology, vol.10, issue.1, p.94, 2016.

J. G. Zanudo and R. Albert, Cell fate reprogramming by control of intracellular network dynamics, PLoS Computational Biology, vol.11, issue.4, p.1004193, 2015.

C. Biane, F. Delaplace, and T. Melliti, Abductive network action inference for targeted therapy, Electronic Notes in Theoretical Computer Science, vol.335, pp.3-25, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01779429

C. Pizzuti, Computing prime implicants by integer programming, Proceedings Eighth IEEE International Conference on Tools with Artificial Intelligence, pp.332-336, 1996.

A. Mishchenko, An introduction to zero-suppressed binary decision diagrams, Proceedings of the 12th Symposium on the Integration of Symbolic Computation and Mechanized Reasoning, vol.8, pp.1-15, 2001.

H. Andersen, Lecture notes for 49285 Advanced Algorithms E97, available online, 1997.

R. E. Bryant, Graph-based algorithms for boolean function manipulation, IEEE Transactions on Computers, vol.100, issue.8, pp.677-691, 1986.

D. Hanahan and R. A. Weinberg, Hallmarks of cancer: the next generation, Cell, vol.144, issue.5, pp.646-674, 2011.

W. Kolch, M. Halasz, M. Granovskaya, and B. N. Kholodenko, The dynamic control of signal transduction networks in cancer cells, Nature Reviews Cancer, 2015.

S. A. Narod and W. D. Foulkes, BRCA1 and BRCA2: 1994 and beyond, Nature Reviews Cancer, vol.4, issue.9, pp.665-676, 2004.

A. Ciliberto, B. Novák, and J. J. Tyson, Steady states and oscillations in the p53/Mdm2 network, Cell Cycle, vol.4, issue.3, pp.488-493, 2005.

S. Von-der-heyde, C. Bender, F. Henjes, J. Sonntag, U. Korf et al., Boolean ErbB network reconstructions and perturbation simulations reveal individual drug response in different breast cancer cell lines, BMC Systems Biology, vol.8, issue.1, p.75, 2014.

M. Kanehisa, M. Furumichi, M. Tanabe, Y. Sato, and K. Morishima, KEGG: new perspectives on genomes, pathways, diseases and drugs, Nucleic Acids Research, vol.45, issue.D1, pp.353-361, 2017.

L. Perfetto, L. Briganti, A. Calderone, A. C. Perpetuini, M. Iannuccelli et al., SIGNOR: A database of causal relationships between biological entities, Nucleic Acids Research, vol.44, issue.D1, pp.548-554, 2016.

C. Biane and F. Delaplace, Abduction based drug target discovery using boolean control network, Proceedings Computational Methods in Systems Biology -15th International Conference, pp.57-73, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01522072

V. Baldin, J. Lukas, M. Marcote, M. Pagano, and G. Draetta, Cyclin D1 is a nuclear protein required for cell cycle progression in G1, Genes & Development, vol.7, issue.5, pp.812-821, 1993.

S. Gupta, Molecular signaling in death receptor and mitochondrial pathways of apoptosis, International Journal of Oncology, vol.22, issue.1, pp.15-20, 2003.

M. Spiliotaki, D. Mavroudis, K. Kapranou, H. Markomanolaki, G. Kallergi et al., Evaluation of proliferation and apoptosis markers in circulating tumor cells of women with early breast cancer who are candidates for tumor dormancy, Breast Cancer Research, vol.16, issue.6, p.485, 2014.

J. Aguirre-ghiso, Models, mechanisms and clinical evidence for cancer dormancy, Nature Reviews Cancer, vol.7, issue.11, p.834, 2007.

C. Kandoth, M. D. Mclellan, F. Vandin, K. Ye, B. Niu et al., Mutational landscape and significance across 12 major cancer types, Nature, vol.502, issue.7471, pp.333-339, 2013.

L. N. Burga, H. Hu, A. Juvekar, N. M. Tung, S. L. Troyan et al., Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice, Breast Cancer Research, vol.13, issue.2, p.30, 2011.

C. M. Croce, Oncogenes and cancer, New England Journal of Medicine, vol.358, issue.5, p.18234754, 2008.

H. Lodish and S. L. Zipursky, Molecular cell biology, Biochemistry and Molecular Biology Education, vol.29, pp.126-133, 2001.

H. Farmer, N. Mccabe, C. J. Lord, A. N. Tutt, D. A. Johnson et al., Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy, Nature, vol.434, issue.7035, pp.917-921, 2005.

L. Livraghi and J. E. Garber, PARP inhibitors in the management of breast cancer: current data and future prospects, BMC Medicine, vol.13, issue.1, p.1, 2015.

W. G. Kaelin, The concept of synthetic lethality in the context of anticancer therapy, Nature Reviews Cancer, vol.5, issue.9, pp.689-98, 2005.

J. Y. Lee, M. Hong, S. T. Kim, S. H. Park, W. K. Kang et al.,

J. Kim and . Lee, The impact of concomitant genomic alterations on treatment outcome for trastuzumab therapy in HER2-positive gastric cancer, Scientific Reports, vol.5, p.9289, 2015.

G. M. Botting, I. Rastogi, G. Chhabra, M. Nlend, and N. Puri, Mechanism of resistance and novel targets mediating resistance to EGFR and c-Met tyrosine kinase inhibitors in non-small cell lung cancer, PloS One, vol.10, issue.8, p.136155, 2015.

X. Wang, A. Q. Fu, M. E. Mcnerney, and K. P. White, Widespread genetic epistasis among cancer genes, Nature Communications, vol.5, 2014.

P. C. Phillips, Epistasis -the essential role of gene interactions in the structure and evolution of genetic systems, Nature Reviews Genetics, vol.9, issue.11, pp.855-867, 2008.

B. Vogelstein, N. Papadopoulos, V. E. Velculescu, S. Zhou, L. A. Diaz et al., Cancer genome landscapes, Science, vol.339, issue.6127, pp.1546-1558, 2013.